Marksans Pharma Ltd. Financials: Quarterly Results
Revenue
774.57
Cr.
PAT
113.69
Cr.
EBITDA
156.56
Cr.
Marksans Pharma Ltd. Q3FY26 Financial Metrics
| Indicator | Dec-25 | Sep-25 | Jun-25 | Mar-25 | Dec-24 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 754.43 | 720.41 | 619.99 | 708.46 | 681.85 |
| Total Income From Operations (Cr.) | 754.43 | 720.41 | 619.99 | 708.46 | 681.85 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 156.56 | 139.15 | 82.66 | 119.53 | 145.93 |
| P/L Before Exceptional Items & Tax (Cr.) | 150.62 | 133.33 | 76.60 | 116.09 | 143.26 |
| P/L After Tax from Ordinary Activities (Cr.) | 113.69 | 99.14 | 58.20 | 90.73 | 105.07 |
| Net Profit/Loss For the Period (Cr.) | 113.69 | 99.14 | 58.20 | 90.73 | 105.07 |
| Basic EPS | 2.50 | 2.17 | 1.29 | 2 | 2.31 |
FAQs
Marksans Pharma Ltd. announced its quarterly results for Q3 FY2026 on February 5, 2026.
In Q3 FY2026, Marksans Pharma Ltd. are as follows:
Revenue: ₹774.57 crore
Net Profit: ₹113.69 crore.
For Q3 FY2026, Marksans Pharma Ltd. posted ₹774.57 crore in revenue and ₹113.69 crore in net profit.
Past quarterly results for Marksans Pharma Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.